Portugal's Hovione surpasses $100 million mark
This article was originally published in Scrip
Increased drug approvals in the innovator and generics sectors have helped Portugal’s Hovione – specialists in API development – reach landmark sales of $103.7 million for the year ending March 31st, says the Portuguese group. Sales grew by 11% in comparison with the previous year, for the first time exceeding $100 million. The group expects soon to be ahead of target for achieving sales worth $150 million by 2010, according to Guy Villax, Hovione's chief executive. Last December the group acquired a 75% stake in the Chinese company Zhejang Taizhou Pharmaceuticals, which it hopes will be the launch pad for operating in Hong Kong and Macau.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.